METex14相关的NSCLC如何治疗?FDA对MET抑制剂Tabrecta持积极态度

2020-05-07 Allan MedSci原创

诺华制药公司近日表示,美国FDA加快了对Tabrecta(capmatinib)申请的审批,以治疗转移性非小细胞肺癌(NSCLC)的成年患者,这些患者肿瘤的突变导致MET的14号外显子跳跃(METex

诺华制药公司近日表示,美国FDA加快了对Tabrecta(capmatinib)申请的审批,以治疗转移性非小细胞肺癌(NSCLC)的成年患者,这些患者肿瘤的突变导致MET的14号外显子跳跃(METex14)。

FDA的决定是基于一项关键性、非随机性的II期GEOMETRY mono-1临床试验的最新结果,该试验评估了每天两次接受Tabrecta(capmatinib)治疗的97名METex14局部晚期或转移性NSCLC患者。结果显示,先前未经治疗的患者的总体缓解率(ORR)为68%,反应持续时间为12.6个月;而先前接受过治疗的患者的总体缓解率(ORR)为41%,反应持续时间为9.7个月。常见的与治疗相关的不良反应事件为水肿、恶心、疲劳、呕吐、呼吸困难和食欲下降。

目前,非小细胞肺癌(non-small cell lung cancer, NSCLC)仍然是人类死亡率最高的恶性肿瘤之一,已经成为严重威胁人们生命健康的社会问题。

 

原始出处:

https://www.firstwordpharma.com/node/1721926?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1896649, encodeId=a60018966497a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 03 09:41:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849924, encodeId=c5591849924f2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Jan 29 15:41:00 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852361, encodeId=e2dd18523612e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 07 21:41:00 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981909, encodeId=ca8d19819092a, content=<a href='/topic/show?id=b5b31163260' target=_blank style='color:#2F92EE;'>#MET抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11632, encryptionId=b5b31163260, topicName=MET抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Sat Nov 07 09:41:00 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477161, encodeId=c18814e7161ff, content=<a href='/topic/show?id=41521e069a2' target=_blank style='color:#2F92EE;'>#Tabrecta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17069, encryptionId=41521e069a2, topicName=Tabrecta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5237352912, createdName=Tamikia, createdTime=Sat May 09 01:41:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039771, encodeId=a6b61039e71ab, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu May 07 13:41:00 CST 2020, time=2020-05-07, status=1, ipAttribution=)]
    2020-06-03 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=1896649, encodeId=a60018966497a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 03 09:41:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849924, encodeId=c5591849924f2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Jan 29 15:41:00 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852361, encodeId=e2dd18523612e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 07 21:41:00 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981909, encodeId=ca8d19819092a, content=<a href='/topic/show?id=b5b31163260' target=_blank style='color:#2F92EE;'>#MET抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11632, encryptionId=b5b31163260, topicName=MET抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Sat Nov 07 09:41:00 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477161, encodeId=c18814e7161ff, content=<a href='/topic/show?id=41521e069a2' target=_blank style='color:#2F92EE;'>#Tabrecta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17069, encryptionId=41521e069a2, topicName=Tabrecta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5237352912, createdName=Tamikia, createdTime=Sat May 09 01:41:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039771, encodeId=a6b61039e71ab, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu May 07 13:41:00 CST 2020, time=2020-05-07, status=1, ipAttribution=)]
    2021-01-29 windight
  3. [GetPortalCommentsPageByObjectIdResponse(id=1896649, encodeId=a60018966497a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 03 09:41:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849924, encodeId=c5591849924f2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Jan 29 15:41:00 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852361, encodeId=e2dd18523612e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 07 21:41:00 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981909, encodeId=ca8d19819092a, content=<a href='/topic/show?id=b5b31163260' target=_blank style='color:#2F92EE;'>#MET抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11632, encryptionId=b5b31163260, topicName=MET抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Sat Nov 07 09:41:00 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477161, encodeId=c18814e7161ff, content=<a href='/topic/show?id=41521e069a2' target=_blank style='color:#2F92EE;'>#Tabrecta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17069, encryptionId=41521e069a2, topicName=Tabrecta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5237352912, createdName=Tamikia, createdTime=Sat May 09 01:41:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039771, encodeId=a6b61039e71ab, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu May 07 13:41:00 CST 2020, time=2020-05-07, status=1, ipAttribution=)]
    2020-12-07 jklm09
  4. [GetPortalCommentsPageByObjectIdResponse(id=1896649, encodeId=a60018966497a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 03 09:41:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849924, encodeId=c5591849924f2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Jan 29 15:41:00 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852361, encodeId=e2dd18523612e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 07 21:41:00 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981909, encodeId=ca8d19819092a, content=<a href='/topic/show?id=b5b31163260' target=_blank style='color:#2F92EE;'>#MET抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11632, encryptionId=b5b31163260, topicName=MET抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Sat Nov 07 09:41:00 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477161, encodeId=c18814e7161ff, content=<a href='/topic/show?id=41521e069a2' target=_blank style='color:#2F92EE;'>#Tabrecta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17069, encryptionId=41521e069a2, topicName=Tabrecta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5237352912, createdName=Tamikia, createdTime=Sat May 09 01:41:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039771, encodeId=a6b61039e71ab, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu May 07 13:41:00 CST 2020, time=2020-05-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1896649, encodeId=a60018966497a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 03 09:41:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849924, encodeId=c5591849924f2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Jan 29 15:41:00 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852361, encodeId=e2dd18523612e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 07 21:41:00 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981909, encodeId=ca8d19819092a, content=<a href='/topic/show?id=b5b31163260' target=_blank style='color:#2F92EE;'>#MET抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11632, encryptionId=b5b31163260, topicName=MET抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Sat Nov 07 09:41:00 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477161, encodeId=c18814e7161ff, content=<a href='/topic/show?id=41521e069a2' target=_blank style='color:#2F92EE;'>#Tabrecta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17069, encryptionId=41521e069a2, topicName=Tabrecta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5237352912, createdName=Tamikia, createdTime=Sat May 09 01:41:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039771, encodeId=a6b61039e71ab, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu May 07 13:41:00 CST 2020, time=2020-05-07, status=1, ipAttribution=)]
    2020-05-09 Tamikia
  6. [GetPortalCommentsPageByObjectIdResponse(id=1896649, encodeId=a60018966497a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 03 09:41:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849924, encodeId=c5591849924f2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Jan 29 15:41:00 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852361, encodeId=e2dd18523612e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 07 21:41:00 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981909, encodeId=ca8d19819092a, content=<a href='/topic/show?id=b5b31163260' target=_blank style='color:#2F92EE;'>#MET抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11632, encryptionId=b5b31163260, topicName=MET抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Sat Nov 07 09:41:00 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477161, encodeId=c18814e7161ff, content=<a href='/topic/show?id=41521e069a2' target=_blank style='color:#2F92EE;'>#Tabrecta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17069, encryptionId=41521e069a2, topicName=Tabrecta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5237352912, createdName=Tamikia, createdTime=Sat May 09 01:41:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039771, encodeId=a6b61039e71ab, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu May 07 13:41:00 CST 2020, time=2020-05-07, status=1, ipAttribution=)]
    2020-05-07 肿肿

    NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了

    0

相关资讯

AACR 2020:大样本NSCLC中的FGFR基因突变结果发布

成纤维细胞生长因子受体(FGFR)信号功能异常在NSCLC中,尤其是肺鳞癌中较为常见。最近一项大样本研究结果发布在今日开幕的AACR大会上,题目为:

AACR 2020:Durvalumab治疗III期不可切除NSCLC的吸烟状态亚组分析

PACIFIC是第一项证明能够改善无法切除的III期非小细胞肺癌(NSCLC)生存的研究,将改写III期NSCLC的治疗标准。III期无法切除NSCLC的5年生存率为15%~30%左右,在长达几十年中

AACR 2020:Capmatinib治疗MET 14突变的NSCLC脑转移疗效

NSCLC是一种常见的肺癌类型,每年影响人数超过200万人,据估计,有3%~4%的NSCLC患者具有MET突变。Capmatinib是目前全球唯一上市的选择性MET抑制剂。

AACR 2020:波奇替尼治疗NSCLC的EGFR 20ins的II期研究

EGFR突变是非小细胞肺癌中最常见的靶点,不过同样是EGFR突变,为何部分患者靶向治疗的效果更差或者很快耐药。其中一项重要的原因就是EGFR上还存在一些罕见突变,比如20ins、G719x、L861Q

姚煜教授:抗血管生成单抗联合TKI治疗有望成为EGFR 21L858R突变晚期NSCLC治疗金标准

众所周知,EGFR 19外显子缺失突变(19del)和21外显子L858R突变(21L858R)对EGFR TKI的敏感性存在差异。在不久前公布的CTONG 1509研究亦指出,21L858R患者接受

AACR 2020:基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS(FLAURA研究)

近年来,多项研究显示,肿瘤内存在多种不同的亚克隆细胞群,即肿瘤异质性。这些瘤内异质性的存在,使得临床实践中单一部位取材的肿瘤标本和基因测序并不能够如实得反映肿瘤内亚克隆的多样性,从而导致无法检测到其中

拓展阅读

ELCC 2024 :围手术期纳武利尤单抗与新辅助化疗+后续辅助纳武利尤单抗治疗可切除NSCLC患者的健康相关生活质量结果(CheckMate 77T研究)

与化疗/安慰剂相比,围手术期NIVO不会对治疗期间的HRQoL产生不利影响,并能降低病情恶化风险。

ELCC 2024 :外泌体生物标志物或可成为非小细胞肺癌(NSCLC)患者预后标志物

外泌体mRNA可作为一种可检测且易获得的生物标志物,为临床的治疗方案选择提供指导。Hippo和HIF1A通路可能在NSCLC中起关键作用,从而提供了潜在的治疗途径。

ELCC 2024:气腔内播散对接受肺叶切除术与肺段切除术治疗的I期NSCLC患者总生存期和无复发生存期的影响

对于伴有STAS的临床I期NSCLC患者,更容易表现为实性结节、脉管浸润、进展分期以及高度侵袭性的病理亚型。肺叶切除术的RFS和OS优于肺段切除术。

多中心研究:对奥希替尼获得性耐药的T790M突变NSCLC更有效

该研究表明,基于抗血管生成的治疗可能改善对奥希替尼获得性耐药的EGFR突变NSCLC患者的PFS和OS。此外,基于安罗替尼的治疗可能是此类患者的一种有前景的有效治疗方法。

2023 WCLC|转移性NSCLC免疫治疗

WCLC是致力于肺癌和其他胸部恶性肿瘤的多学科肿瘤学会议,来自全球100多个国家的7000多名专业人士参会,共同探讨肺癌和其他胸部恶性肿瘤的前沿诊疗进展。

崔彦芝教授:RAS突变晚期NSCLC免疫治疗新话题

近年来,RAS突变引起了研究人员的广泛关注,并被认为可能是预测该免疫治疗疗效的一个生物标志物。